Consumer advocacy group Public Citizen responds to Mylan announcement of cheaper, generic EpiPen: 'The weirdness of a generic drug company offering a generic version of its own branded but off-patent product is a signal that something is wrong.'
http://www.citizen.org/pressroom/pressroomredirect.cfm?ID=7989